Background
Phase II, single-arm study. 81 patients with R/R DLBCL who were not eligible for ASCT and had received 1–3 prior lines of therapy (including ≥1 rituximab-containing regimen). Tafasitamab is an Fc-enhanced anti-CD19 monoclonal antibody. L-MIND tested tafasitamab + lenalidomide as a non-chemotherapy salvage regimen.
Interventions and follow up
Regimen: Tafasitamab 12 mg/kg IV weekly cycles 1–3 (loading day 4 cycle 1) then every 2 weeks + lenalidomide 25 mg PO days 1–21 every 28d × 12 cycles, then tafasitamab maintenance Q14d, in R/R DLBCL ineligible for autoSCT
Primary endpoint: Overall response rate (independent review committee)
Median follow-up: 35 months (long-term update)
Primary endpoint: Overall response rate (independent review committee)
Median follow-up: 35 months (long-term update)
Results
ORR (primary): 57.5% (95% CI 45.9–68.5%)
CR rate: 40.0%
mDOR (all responders): 43.9 months
mDOR (CR patients): Not reached
mPFS: 11.6 months
mOS: 33.5 months
CR rate: 40.0%
mDOR (all responders): 43.9 months
mDOR (CR patients): Not reached
mPFS: 11.6 months
mOS: 33.5 months
Adverse events
Overall: Grade ≥3 AEs 84%; treatment discontinuation due to AEs 14.8%
Hematologic: Grade ≥3 neutropenia 48.1%, thrombocytopenia 17.3%, anemia 7.4%, febrile neutropenia 12.3%
Hematologic: Grade ≥3 neutropenia 48.1%, thrombocytopenia 17.3%, anemia 7.4%, febrile neutropenia 12.3%
Conclusions
Tafasitamab + lenalidomide demonstrated a 57.5% ORR and durable responses (mDOR 43.9 months) in transplant-ineligible R/R DLBCL, supporting FDA approval. The combination provides a non-cytotoxic salvage option with meaningful durability in responding patients.
Key Limitations
Single-arm Phase II with no randomized comparator and small sample size (n=81). Enrolled population skewed toward fewer prior lines (favorable prognosis) and excluded primary refractory disease, limiting generalizability to heavily pretreated patients. Loss of CD19 antigen after tafasitamab may compromise subsequent CD19-directed CAR-T efficacy, a relevant sequencing concern. Indirect comparison RE-MIND used historical lenalidomide-monotherapy controls.
Clinical Context
FDA granted accelerated approval of tafasitamab (Monjuvi) + lenalidomide in July 2020 for R/R DLBCL not eligible for ASCT; EMA approved (Minjuvi) in 2021. ESMO and ASCO guidance include tafasitamab-lenalidomide as a non-chemotherapy option for transplant-ineligible R/R DLBCL. Optimal sequencing relative to CD19 CAR-T remains an active question given shared CD19 target.